SCHEMBL2173418

SCHEMBL2173418

N#Cc1cccc(NC(=O)c2ccccc2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.71
F2 P00734 1/20 0.71
PLG P00747 1/20 0.71
PLAU P00749 1/20 0.71
KLKB1 P03952 1/20 0.71
PRSS1 P07477 1/20 0.71
KCNK3 O14649 1/20 0.69
KCNK9 Q9NPC2 1/20 0.69
GRM4 Q14833 1/20 0.65
NAMPT P43490 1/20 0.63
LMNA P02545 1/20 0.62
ALDH1A1 P00352 2/20 0.62
MAPT P10636 2/20 0.62
NR1H4 Q96RI1 1/20 0.62
SIRT1 Q96EB6 1/20 0.61
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
HPGD P15428 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13210705 0.93 NAMPT (0.66) HTTF2PLGPLAUKLKB1
SCHEMBL31219284 0.90 HTT (0.62) HTTF2PLGPLAUKLKB1
SCHEMBL15788186 0.89 MAPK14 (0.66) HTTF2PLGPLAUKLKB1
SCHEMBL6655548 0.86 KMT2A (0.66) HTTF2PLGPLAUKLKB1
SCHEMBL94618 0.86 NAMPT (0.59) HTTF2PLGPLAUKLKB1
SCHEMBL7379264 0.85 KCNK3 (0.71) KCNK3KCNK9ALDH1A1MAPTSIRT1
SCHEMBL14187585 0.85 PTGS1 (0.62) HTTF2PLGPLAUKLKB1
Hydrochloric Acid SCHEMBL2104599 0.85 HTT (0.60) HTTF2PLGPLAUKLKB1
SCHEMBL4252916 0.85 KCNK3 (0.72) KCNK3KCNK9MAPTMEN1KMT2A
SCHEMBL5612900 0.84 KCNK3 (0.69) KCNK3KCNK9SIRT1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4006035-B1 QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER NEUPHARMA INC (US) 2023-11-22 EP claimed
EP-1068187-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 2001-01-17 EP claimed
WO-1999051580-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 1999-10-14 WO claimed
US-12269814-B2 Process for preparing a compound useful to treat mycoses PULMOCIDE LIMITED (GB) 2025-04-08 US disclosed
US-11661415-B2 Process for preparing a compound useful to treat mycoses PULMOCIDE LIMITED (GB) 2023-05-30 US disclosed
US-20110172203-A1 Substituted Imidazopyridinyl-Aminopyridine Compounds ARQULE, INC. (US) 2011-07-14 US disclosed
WO-2011082270-A2 SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS ARQULE. INC. (US) 2011-07-07 WO disclosed
CN-100335468-C Diaryl amidine compound, its production, medicinal composition and use DRUG INST CHINESE ACADEMY OF M (CN) 2007-09-05 CN disclosed
CN-1712398-A Diaryl amidine compound, its production, medicinal composition and use DRUG INST CHINESE ACADEMY OF M (CN) 2005-12-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661415-B2 Process for preparing a compound useful to treat mycoses DPM1, CYP51A1, ERG28 HTT 4807/4885F2 196/4885PLG 2030/4885
US-20110172203-A1 Substituted Imidazopyridinyl-Aminopyridine Compounds MKI67, CDK4, ABL1 HTT 939/4885F2 4072/4885PLG 4254/4885
US-12269814-B2 Process for preparing a compound useful to treat mycoses C1R, CBR1, CBR3 HTT 1887/4885F2 2967/4885PLG 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.